Thus, researchers have realized that it is worth to focus strength on studying the escape mechanisms of HBV to interfere with TLR9 activity in HCC or chronic infection.[62] In addition, the preclinical study has shown promise for a novel TLR-9 agonist C792 to treat multiple myeloma (MM), in which C792 significantly improves immune function and overcomes drug resistance in MM.[63]. Here, TLR9 is linked to plasma cell myeloma.